Meridian Bioscience, Inc. (VIVO) Misses Q2 EPS by 2c, Reiterates Outlook
Get Alerts VIVO Hot Sheet
Price: $33.97 --0%
Revenue Growth %: -100.0%
Financial Fact:
BASIC EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
TOWN, NRIM, GCBC, More
Revenue Growth %: -100.0%
Financial Fact:
BASIC EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
TOWN, NRIM, GCBC, More
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.18, $0.02 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $41.1 million versus the consensus estimate of $41.2 million.
Meridian Bioscience, Inc. is reiterating its guidance and sees FY2011 EPS of $0.77-$0.82, versus the consensus of $0.78. Meridian Bioscience, Inc. sees FY2011 revenue of $165-$170 million, versus the consensus of $165.55 million.
Meridian Bioscience, Inc. is reiterating its guidance and sees FY2011 EPS of $0.77-$0.82, versus the consensus of $0.78. Meridian Bioscience, Inc. sees FY2011 revenue of $165-$170 million, versus the consensus of $165.55 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Alamos Gold (AGI) Misses Q1 EPS by 1c
- O'Reilly Automotive (ORLY) Misses Q1 EPS by 7c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!